These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 37079100)

  • 1. Remimazolam: a new string to the TIVA bow.
    Hirota K
    J Anesth; 2023 Jun; 37(3):335-339. PubMed ID: 37079100
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic benefits of remimazolam compared to midazolam and propofol for procedural sedation in colonoscopies and bronchoscopies.
    Pedersen MH; Danø A; Englev E; Kattenhøj L; Munk E
    Curr Med Res Opin; 2023 May; 39(5):691-699. PubMed ID: 36999319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remimazolam: a new reminder to keep our guard up.
    Abad-Gurumeta A; Gómez-Ríos MA
    Minerva Anestesiol; 2023 Jun; 89(6):495-497. PubMed ID: 37158630
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of concurrent remifentanil on the sedative effects of remimazolam, midazolam and propofol in cynomolgus monkeys.
    Kops MS; Pesic M; Petersen KU; Schmalix WA; Stöhr T
    Eur J Pharmacol; 2021 Jan; 890():173639. PubMed ID: 33065095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Awaiting remimazolam guidance.
    Wootton J; Forrest M
    Br Dent J; 2023 Jan; 234(2):73. PubMed ID: 36707554
    [No Abstract]   [Full Text] [Related]  

  • 6. Remimazolam should be antagonized by an adequate flumazenil.
    Sato T; Nishiwaki K
    J Anesth; 2023 Feb; 37(1):164-165. PubMed ID: 36197518
    [No Abstract]   [Full Text] [Related]  

  • 7. Tolerance to remimazolam at a high effect-site concentration.
    Kida K; Taguchi M; Uchiyama K; Fujioka S; Tsubokawa T
    J Anesth; 2023 Feb; 37(1):168-169. PubMed ID: 36449088
    [No Abstract]   [Full Text] [Related]  

  • 8. What May Be the First Phase 4 Experience with BYFAVO (Remimazolam).
    Henson KS; Thompson KJ
    AANA J; 2021 Apr; 89(2):101-102. PubMed ID: 33832568
    [No Abstract]   [Full Text] [Related]  

  • 9. Re-sleeping after reversal of remimazolam by flumazenil.
    Yamamoto T; Kurabe M; Kamiya Y
    J Anesth; 2021 Apr; 35(2):322. PubMed ID: 33687549
    [No Abstract]   [Full Text] [Related]  

  • 10. Remimazolam for anaesthesia or sedation.
    Sneyd JR; Rigby-Jones AE
    Curr Opin Anaesthesiol; 2020 Aug; 33(4):506-511. PubMed ID: 32530890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electroencephalogram inability to detect intraoperative awakening in a patient with remimazolam tolerance.
    Kawashima S; Kinoshita H; Kawashima W; Nakajima Y
    Minerva Anestesiol; 2023 May; 89(5):482-483. PubMed ID: 36383081
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiac Arrest Following Remimazolam-Induced Anaphylaxis: A Case Report.
    Hasushita Y; Nagao M; Miyazawa Y; Yunoki K; Mima H
    A A Pract; 2022 Sep; 16(9):e01616. PubMed ID: 36149988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficiency and safety of remimazolam and midazolam in digestive endoscopic sedation: Systematic review and meta-analysis.
    Dou D; Feng Y; Jiang L
    Dig Endosc; 2022 Mar; 34(3):653. PubMed ID: 34918386
    [No Abstract]   [Full Text] [Related]  

  • 14. A Phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy.
    Borkett KM; Riff DS; Schwartz HI; Winkle PJ; Pambianco DJ; Lees JP; Wilhelm-Ogunbiyi K
    Anesth Analg; 2015 Apr; 120(4):771-80. PubMed ID: 25502841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting the amount of flumazenil needed to antagonize remimazolam.
    Aya D; Hoshi T; Yamaguchi H
    Eur J Gastroenterol Hepatol; 2021 Oct; 33(10):1335-1336. PubMed ID: 34581692
    [No Abstract]   [Full Text] [Related]  

  • 16. Simulation of residual sedation effect of remimazolam: pharmacokinetic-pharmacodynamic simulation can be an additional standard anesthesia monitoring method.
    Obara S
    J Anesth; 2022 Apr; 36(2):167-170. PubMed ID: 34160699
    [No Abstract]   [Full Text] [Related]  

  • 17. Remimazolam besylate for sedation of postoperative patients in intensive care units: a phase I, open label, dose-finding study.
    Tang Y; Yang X; Shu H; Yu Y; Xu J; Pan S; Zou X; Yuan S; Shang Y
    Chin Med J (Engl); 2022 Sep; 135(17):2134-2136. PubMed ID: 36191588
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy.
    Pambianco DJ; Borkett KM; Riff DS; Winkle PJ; Schwartz HI; Melson TI; Wilhelm-Ogunbiyi K
    Gastrointest Endosc; 2016 May; 83(5):984-92. PubMed ID: 26363333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remimazolam: new beginnings or just a me-too?
    Sneyd JR
    Anesth Analg; 2012 Aug; 115(2):217-9. PubMed ID: 22826518
    [No Abstract]   [Full Text] [Related]  

  • 20. Context sensitive decrement times of remimazolam.
    Schnider T; Minto C
    Anesth Analg; 2013 Jul; 117(1):285. PubMed ID: 23788743
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.